Company / Financials
Edwards Lifesciences Financials
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$6.1B
FY2025 · +11.5% YoY
Net Income
$1.1B
FY2025 · -74.3% YoY
Profit Margin
17.7%
FY2025 · net income / revenue
ROE
10.4%
FY2025 · return on equity
Total Assets
$13.7B
FY2025
Total Debt
$598.3M
0.06x debt/equity
Equity
$10.3B
FY2025
ROA
7.8%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score 3.16 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$6.1B+11.5% YoYNet Income HistoryProfit after all expenses and taxes$1.1B-74.3% YoYGross Profit HistoryRevenue minus cost of goods sold$4.7B+9.5% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$1.3B+19.4% YoYOperating Income HistoryProfit from core business operations before interest and taxes$1.3B-8.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$2.1B+16.5% YoYR&D Expense HistoryResearch and development spending$1.1B+2.5% YoYInterest Expense HistoryCost of borrowing and debt obligations-$20.4MIncome Tax HistoryTotal income tax expense$216.9M+42.6% YoYEPS (Basic) HistoryBasic earnings per share$1.84-25.2% YoY